miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Al harbi, Sayer ^a,e   Choudhary, Gaurav S ^a,f   Ebron, Jey Sabith ^g   Hill, Brian T ^d   Vivekanathan, Nagarajavel ^b   Ting, Angela H ^b   Radivoyevitch, Tomas ^c   Smith, Mitchell R ^d   Shukla, Girish C ^g   Almasan, Alex ^a  

^a Departments of Cancer Biology   (United States)

^b Genomic Medicine Institute   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CLEVELAND STATE UNIVERSITY   (United States)

Author keywords

14q32 miRNA cluster; BCL 2 family gene expression; BCL xL; Chronic lymphocytic leukemia; Micro RNA; MiR 377

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; BENDAMUSTINE; CHLORAMBUCIL; FLUDARABINE; MICRORNA; MICRORNA 377; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; PREDNISONE; PROTEIN BCL XL; PURINE DERIVATIVE; RITUXIMAB; UNCLASSIFIED DRUG; FUSED HETEROCYCLIC RINGS; MIRN377 MICRORNA, HUMAN; PROTEIN BCL X; SULFONAMIDE; VENETOCLAX;

3' UNTRANSLATED REGION; ABT 199 CELL; ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B CELL LYMPHOMA CELL; BINDING SITE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CELL LINE; CHROMOSOME 4Q; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; GENE CLUSTER; GENE LOCATION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEIN RNA BINDING; REGULATORY MECHANISM; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; DRUG RESISTANCE; GENETICS; METABOLISM; MUTATION;

ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BCL-X PROTEIN; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICRORNAS; MUTATION; SULFONAMIDES;

EID: 84946398512     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-015-0460-8     Document Type: Article

References (55)

1. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer. 2008;8(2):121-32.
2. Del Gaizo MV, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clinical Investig. 2007;117(1):112-21.
3. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007;12(2):171-85.
4. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11(9):621-32.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
6. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011;334(6059):1129-33.
7. Thomas A, Pepper C, Hoy T, Bentley P. Bcl-2 and bax expression and chlorambucil-induced apoptosis in the T-cells and leukaemic B-cells of untreated B-cell chronic lymphocytic leukaemia patients. Leuk Res. 2000;24(10):813-21.
8. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L, et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood. 2008;112(9):3807-17.
9. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, et al. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res. 2007;13(7):2144-50.
10. Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol. 2012;30(25):3127-35.
11. Al-Harbi S, Hill BT, Mazumder S, Singh K, Devecchio J, Choudhary G, et al. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood. 2011;118(13):3579-90.
12. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202-8.
13. Alford SE, Kothari A, Loeff FC, Eichhorn JM, Sakurikar N, Goselink HM, et al. BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells. Cancer Res. 2015;75(7):1366-75.
14. Garber K. Kinase inhibitors overachieve in CLL. Nat Rev Drug Discov. 2014;13(3):162-4.
15. Dalla-Favera R. Lymphoid malignancies: many tumor types, many altered genes, many therapeutic challenges. J Clinical Investig. 2012;122(10):3396-7.
16. Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M. Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood. 1987;69(3):929-36.
17. Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol. 1998;25(1):42-59.
18. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-15.
19. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351(9):893-901.
20. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-7.
21. Van Bockstaele F, Verhasselt B, Philippe J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev. 2009;23(1):25-47.
22. Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med. 2006;145(6):435-47.
23. Shindiapina P, Brown JR, Danilov AV. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. British J Haematol. 2014;167(2):149-61.
24. Bottcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980-8.
25. Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015;29(2):329-36.
26. Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clinical Investig. 2013;123(6):2395-407.
27. Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol. 2013;15(6):546-54.
28. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids--the mix of hormones and biomarkers. Nature reviews Clinical Oncol. 2011;8(8):467-77.
29. Bai M, Skyrlas A, Agnantis NJ, Kamina S, Tsanou E, Grepi C, et al. Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl. Modern Pathol. 2004;17(7):847-56.
30. Mazumder S, Choudhary GS, Al-Harbi S, Almasan A. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Res. 2012;72(12):3069-79.
31. Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death & Disease. 2015;6:e1593.
32. Grad JM, Zeng XR, Boise LH. Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Current Opinion Oncol. 2000;12(6):543-9.
33. Reindl L, Bacher U, Dicker F, Alpermann T, Kern W, Schnittger S, et al. Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms. British J Haematol. 2010;151(1):25-36.
34. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006;66(15):7390-4.
35. Lujambio A, Esteller M. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle. 2007;6(12):1455-9.
36. Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro E, Levine AJ, et al. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene. 2014;33(44):5173-82.
37. Nadal E, Zhong J, Lin J, Reddy RM, Ramnath N, Orringer MB, et al. A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma. Clin Cancer Res. 2014;20(12):3107-17.
38. Rossi D, Gaidano G. Richter syndrome. Advances Exp Med Biol. 2013;792:173-91.
39. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A. 2008;105(19):7004-9.
40. Lu Y, Govindan R, Wang L, Liu PY, Goodgame B, Wen W, et al. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis. 2012;33(5):1046-54.
41. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899-905.
42. Cosson A, Chapiro E, Belhouachi N, Cung HA, Keren B, Damm F, et al. 14q deletions are associated with trisomy 12, NOTCH1 mutations and unmutated IGHV genes in chronic lymphocytic leukemia and small lymphocytic lymphoma. Genes, Chromosomes & Cancer. 2014;53(8):657-66.
43. Manodoro F, Marzec J, Chaplin T, Miraki-Moud F, Moravcsik E, Jovanovic JV, et al. Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia. Blood. 2014;123(13):2066-74.
44. Zehavi L, Schayek H, Jacob-Hirsch J, Sidi Y, Leibowitz-Amit R, Avni D. MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in malignant melanoma. Mol Cancer. 2015;14:68.
45. Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005;10(3):176-82.
46. Amatori S, Bagaloni I, Donati B, Fanelli M. DNA demethylating antineoplastic strategies: a comparative point of view. Genes & cancer. 2010;1(3):197-209.
47. Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B, et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dpendency. Cancer Cell. 2012;21(4):547-62.
48. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace Jr AJ. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 2000;60(21):6101-10.
49. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol. 2007;25(7):799-804.
50. Sheikholeslami MR, Jilani I, Keating M, Uyeji J, Chen K, Kantarjian H, et al. Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis. Cytometry B Clin Cytom. 2006;70(4):270-5.
51. Zhao WL, Daneshpouy ME, Mounier N, Briere J, Leboeuf C, Plassa LF, et al. Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood. 2004;103(2):695-7.
52. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-82.
53. Sikand K, Slaibi JE, Singh R, Slane SD, Shukla GC. miR 488* inhibits androgen receptor expression in prostate carcinoma cells. Int J Cancer. 2011;129(4):810-9.
54. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 2001;8(3):705-11.
55. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 2005;33(17):5394-403.